SRX1077028 GSM1726477 SRP059958 SRS975926 GSM1726477 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726477 GEO Accession GSM1726477 SRX1077029 GSM1726478 SRP059958 SRS975931 GSM1726478 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726478 GEO Accession GSM1726478 SRX1077030 GSM1726479 SRP059958 SRS975927 GSM1726479 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726479 GEO Accession GSM1726479 SRX1077031 GSM1726480 SRP059958 SRS975930 GSM1726480 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726480 GEO Accession GSM1726480 SRX1077032 GSM1726481 SRP059958 SRS975925 GSM1726481 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726481 GEO Accession GSM1726481 SRX1077033 GSM1726482 SRP059958 SRS975929 GSM1726482 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726482 GEO Accession GSM1726482 SRX1077034 GSM1726483 SRP059958 SRS975928 GSM1726483 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726483 GEO Accession GSM1726483 SRX1077035 GSM1726484 SRP059958 SRS975922 GSM1726484 RNA-Seq TRANSCRIPTOMIC cDNA SCN samples were homogenized in Trizol reagent (Invitrogen) using a Tissuelyser (Qiagen). RNA was extracted using RNeasy columns (Qiagen) as per manufacturer’s protocol, with the modification that 1.5 volumes of 100% ethanol were added to the aqueous phase following centrifugation. Samples were resuspended in 25 uL of RNase free H2O. RNA was quantified by QUBIT (Invitrogen). Equal amounts of SCN RNA from three mice were pooled for each time point. Prepared using Illumina TruSeq Stranded mRNA HT Sample Preparation Kit as per manufacturer’s protocol. Briefly, 0.1 ug of total RNA was polyA-selected, fragmented by metal-ion hydrolysis, and converted into double-stranded cDNA using Invitrogen Superscript II. The cDNA fragments were subjected to end-repair, adenylation, ligation of Illumina sequencing adapters, and PCR amplification. Illumina HiSeq 2000 gds 301726484 GEO Accession GSM1726484